Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (r*,r*)-(+-)-2,3-dihydroxybutanedioic Acid, Monoammonium Monosodium Salt
2. Aluminum Tartrate
3. Ammonium Tartrate
4. Calcium Tartrate
5. Calcium Tartrate Tetrahydrate
6. Mn(iii) Tartrate
7. Potassium Tartrate
8. Seignette Salt
9. Sodium Ammonium Tartrate
10. Sodium Potassium Tartrate
11. Sodium Tartrate
12. Stannous Tartrate
13. Tartaric Acid
14. Tartaric Acid, ((r*,r*)-(+-))-isomer
15. Tartaric Acid, (r*,s*)-isomer
16. Tartaric Acid, (r-(r*,r*))-isomer
17. Tartaric Acid, (s-(r*,r*))-isomer
18. Tartaric Acid, Ammonium Sodium Salt, (1:1:1) Salt, (r*,r*)-(+-)-isomer
19. Tartaric Acid, Calcium Salt, (r-r*,r*)-isomer
20. Tartaric Acid, Monoammonium Salt, (r-(r*,r*))-isomer
21. Tartrate
1. Faecula
2. Faecla
3. Acid Potassium Tartrate
4. Faccula
5. Faccla
6. Tartar
7. Potassium L-bitartrate
8. Tartar Cream
9. Monopotassium Tartrate
10. Cream Of Tartar
11. Potassium Hydrogentartrate
12. Purified Cream Of Tartar
13. Npt6p8p3uu
14. Butanedioic Acid, 2,3-dihydroxy- (2r,3r)-, Monopotassium Salt
15. Potassium Tartrate
16. Ins No.336(i)
17. Ins-336(i)
18. Monopotassium Tartrate (336(i))
19. Cremor Tartari
20. E-336(i)
21. Butanedioic Acid 2,3-dihydroxy-, (r-(r*,r*))-, Monopotassium Salt
22. Potassium L-tartrate
23. Potassium (2r,3r)-3-carboxy-2,3-dihydroxypropanoate
24. Potassium Hydrogen Tartrate (jan)
25. Potassium Hydrogen Tartrate [jan]
26. Potassium Tartrate (khc4h4o6)
27. Tartaric Acid, Monopotassium Salt
28. Nsc-155080
29. Potassium Bitartrate [usan]
30. Potassium Hydrogen L-tartrate
31. Potassium L-tartrate Monobasic
32. Ccris 7329
33. Potassium Acid Salt Of L-(+)-tartaric Acid
34. Tartaric Acid Monopotassium Salt
35. Hsdb 1264
36. Potassium L-tartrate (kc4h5o6)
37. Einecs 212-769-1
38. L(+)-tartaric Acid Monopotassium Salt
39. Nsc 155080
40. Unii-npt6p8p3uu
41. Potassium Bitartrate (usp)
42. Schembl39256
43. L(+)-potassiumhydrogentartrate
44. Chembl2105248
45. Dtxsid6042313
46. Monopotassium 2,3-dihydroxybutanedioate, (r-(r*,r*))-
47. Chebi:32034
48. Potassium Hydrogen (+)-tartrate
49. Potassium Bitartrate [ii]
50. Potassium Bitartrate [mi]
51. Potassium Bitartrate [usan:usp]
52. Potassium Bitartrate [inci]
53. Potassium Bitartrate [vandf]
54. Butanedioic Acid, 2,3-dihydroxy-, (r-(r*,r*))-, Monopotassium Salt
55. Mfcd00065392
56. Potassium Bitartrate [usp-rs]
57. Potassium Bitartrate [who-dd]
58. Akos015915093
59. Butanedioic Acid, 2,3-dihydroxy- (theta-(theta,theta))-, Monopotassium Salt
60. Db11107
61. Potassium Acid Tartrate [mart.]
62. E336
63. Potassium Bitartrate [orange Book]
64. Potassium Bitartrate [usp Impurity]
65. Potassium Bitartrate [usp Monograph]
66. D01561
67. Ec 212-769-1
68. Potassium Hydrogen Tartrate [ep Impurity]
69. Potassium Hydrogen Tartrate [ep Monograph]
70. Butanedioic Acid, 2,3-dihydroxy- (2r,3r)-, Potassium Salt (1:1)
| Molecular Weight | 188.18 g/mol |
|---|---|
| Molecular Formula | C4H5KO6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 187.97231936 g/mol |
| Monoisotopic Mass | 187.97231936 g/mol |
| Topological Polar Surface Area | 118 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 157 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Indicated for the treatment of constipation.
Potassium bitartrate potentiates bowel movements. In medical studies, it was shown to be an effective treatment for chronic constipationwhen combined with sodium bicarbonate in a polyethylene glycol-based suppository.
A - Alimentary tract and metabolism
A12 - Mineral supplements
A12B - Potassium
A12BA - Potassium
A12BA03 - Potassium hydrogentartrate
Absorption
There is little systemic absorption expected following rectal administration of potassium bitartrate.
Route of Elimination
No pharmacokinetic data available.
Volume of Distribution
No pharmacokinetic data available.
Clearance
No pharmacokinetic data available.
No pharmacokinetic data available.
No pharmacokinetic data available.
Potassium bitartrate is a carbon dioxide-releasing laxative that works by forming carbon dioxide gas, which creates a mechanical distension against the intestinal wall and induces bowel contractions. Rectal suppositories of carbon dioxide-releasing type of laxative were demonstrated to be useful and safe in the treatment of patients at risk for electrolyte disorders such as the elderly or patients with renal or cardiovascular disorders.
ABOUT THIS PAGE
A Potassium Hydrogen Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Potassium Hydrogen Tartrate, including repackagers and relabelers. The FDA regulates Potassium Hydrogen Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Potassium Hydrogen Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Potassium Hydrogen Tartrate supplier is an individual or a company that provides Potassium Hydrogen Tartrate active pharmaceutical ingredient (API) or Potassium Hydrogen Tartrate finished formulations upon request. The Potassium Hydrogen Tartrate suppliers may include Potassium Hydrogen Tartrate API manufacturers, exporters, distributors and traders.
Potassium Hydrogen Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Potassium Hydrogen Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Potassium Hydrogen Tartrate GMP manufacturer or Potassium Hydrogen Tartrate GMP API supplier for your needs.
A Potassium Hydrogen Tartrate CoA (Certificate of Analysis) is a formal document that attests to Potassium Hydrogen Tartrate's compliance with Potassium Hydrogen Tartrate specifications and serves as a tool for batch-level quality control.
Potassium Hydrogen Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Potassium Hydrogen Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Potassium Hydrogen Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Potassium Hydrogen Tartrate EP), Potassium Hydrogen Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Potassium Hydrogen Tartrate USP).
LOOKING FOR A SUPPLIER?
